Benjamin F. Edwards & Company, Inc. Bei Gene, Ltd. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.51 Billion
- Q1 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 821 shares of BGNE stock, worth $118,511. This represents 0.0% of its overall portfolio holdings.
Number of Shares
821
Previous 542
51.48%
Holding current value
$118,511
Previous $98,000
30.61%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
216Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.53 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.02 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$747 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$722 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$538 Million0.46% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $15B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...